Statistics

Total Visits

Views
Phase IB/II study of the HSP90 inhibitor AUY922, in combination with trastuzumab, in patients with HER2+ advanced breast cancer27

Select a period of time:

Number of views in the range

Views
Phase IB/II study of the HSP90 inhibitor AUY922, in combination with trastuzumab, in patients with HER2+ advanced breast cancer16

Views

Views
October 20240
November 20240
December 20240
January 20250
February 20250
March 202516
April 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore16
 

Top cities views

Views